Fajun Xie
Overview
Explore the profile of Fajun Xie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
251
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xu Y, Chen K, Xu Y, Li H, Huang Z, Lu H, et al.
Lancet Oncol
. 2025 Jan;
26(1):74-84.
PMID: 39756446
Background: Brain metastases are a common complication in patients with non-small-cell lung cancer (NSCLC) lacking actionable driver mutations, with limited treatment options and poor prognosis. We aimed to investigate the...
2.
Zheng Q, Ou D, Xie F, Chen L
Eur J Radiol
. 2024 Sep;
181:111761.
PMID: 39342886
Objectives: This study aimed to validate the efficacy and safety of contrast-enhanced ultrasound-guided percutaneous transhepatic cholangiodrainage (CEUS-PTCD) as a biliary drainage procedure in patients with malignant biliary obstruction and stage...
3.
Zheng Q, Xie Y, Xu L, Chen D, Wu J, Liu S, et al.
J Gastrointest Oncol
. 2024 Sep;
15(4):1746-1759.
PMID: 39279982
Background: Lactate dehydrogenase A () plays a crucial role in the final step of anaerobic glycolysis, converting L-lactate and NAD to pyruvate and nicotinamide adenine dinucleotide (NADH). Its high expression...
4.
Gong J, Hu S, Shan Q, Qin J, Han N, Xie F, et al.
Ther Adv Med Oncol
. 2024 Mar;
16:17588359241239293.
PMID: 38510678
Background: Bone metastasis (BM) seriously affects the quality of life and reduces the survival time of patients with non-small-cell lung cancer (NSCLC). The genomic characteristics and potential targets of BMs...
5.
Huang Z, Xu Y, Hong W, Gong L, Chen K, Qin J, et al.
Front Immunol
. 2023 Nov;
14:1258573.
PMID: 37936687
Background: QL1604 is a humanized immunoglobulin G4 monoclonal antibody against programmed cell death protein 1. This first-in-human, open-label phase I study aimed to investigate the safety and tolerability and to...
6.
Chen K, Xu Y, Huang Z, Yu X, Hong W, Li H, et al.
Cancer Med
. 2023 Sep;
12(19):19460-19470.
PMID: 37723837
Background: Patients with non-small-cell lung cancer (NSCLC) and uncommon EGFR alterations typically have worse treatment outcomes than patients with classically EGFR-mutated NSCLC. This study aimed to investigate the efficacy and...
7.
Li M, Qin J, Xie F, Gong L, Han N, Lu H
Discov Oncol
. 2022 Aug;
13(1):72.
PMID: 35943592
Osimertinib, a mutant-specific third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is emerging as the preferred first-line of treatment for EGFR-mutant lung cancer. However, osimertinib resistance inevitably develops...
8.
Qin J, Zeng D, Xie F, Yu R, Wu X, Liu K, et al.
Transl Cancer Res
. 2022 Feb;
8(5):2187-2191.
PMID: 35116968
Two patients with rare fusion G13:A20 which were found in Chinese population by next generation sequencing (NGS) developed resistant to crizotinib with a prolonged progression-free survival (PFS). Both patients showed...
9.
Qin J, Xie F, Li C, Han N, Lu H
Pathol Oncol Res
. 2021 Jul;
27:1609775.
PMID: 34257619
The Myc family, especially and , has been found involved in small-cell lung carcinoma (SCLC). Identification of the frequency of C-MYC and MYCL1 expression among SCLC patients may help to...
10.
Qin J, Xie F, Wang F, Lu H
J Cancer
. 2020 Jul;
11(16):4691-4699.
PMID: 32626515
Fibroblast growth factor receptor 1 (FGFR1) alterations have been described in many cancers, including lung cancer, but the role has not been elucidated specifically in small cell lung cancer (SCLC)....